Dr. Broyles is also President of the Sickle Cell Cure Foundation, Inc., a 501c3 nonprofit research corporation founded 2006, is a pioneer in sickle cell research for over 40 years and is the Principal Investigator for the research patented as GRT.

Dr. Floyd previously founded and managed three companies (Centaur Pharmaceuticals, Otologic Pharmaceutics, and Oconos) and therefore has a wealth of experience in the biotechnology sector.

Mr. Roth has been involved in development of EdX-17 and Gene Regulation Therapy for sickle cell disease. He began working part-time in the laboratory of Dr. Broyles in 1999 as a high school student and has been a full-time Research Technician with the Sickle Cell Cure Foundation and EpimedX since inception. Mr. Roth has a BA in Chemistry from the University of Massachusetts Amherst.

Mr. Bricker is a twenty-three year veteran of USAID. He has directed the program budget for several public health projects, including HIV/AIDS treatments in Zambia.

Dr. Belegu is A Senior Research Scientist at the Kennedy Krieger Research Institute of Johns Hopkins Medical School and has over 12 years experience in sickle cell research.

Dr. Curtis joined EpimedX in 2013. She is involved in Proof-of-Concept testing and is responsible for managing all of the aspects of preclinical development of EdX-17. Dr. Curtis earned a PhD from the University of Illinois in 2009 and completed postdoctoral training at the Oklahoma Medical Research Foundation.

Mr. Floyd has worked with 4 start-up biotechnology companies and has more than a decade of experience in laboratory operations management. He is an experienced research technician and accomplished accounts manager. Mr. Floyd manages all aspects of day-to-day financial accounting for EpimedX. He has a BS in Science from Oklahoma City University.